An adaptive multi-arm phase II trial of maintenance targeted therapy after chemotherapy in metastatic urothelial cancer
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms ATLANTIS
- 14 Sep 2017 Planned number of patients changed from 140 to 188.
- 28 Sep 2016 New trial record
- 16 Sep 2016 Status changed from not yet recruiting to recruiting.